search
Back to results

Prednisolone Trial in Children Younger Than 4 Years

Primary Purpose

Nephrotic Syndrome

Status
Unknown status
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Prednisolone
Sponsored by
All India Institute of Medical Sciences, New Delhi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nephrotic Syndrome focused on measuring Proteinuria Hypoproteinemia Edema Hypoalbuminemia Prednisone

Eligibility Criteria

1 Year - 4 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Idiopathic, steroid-sensitive, first episode of nephrotic syndrome
  2. Age 12 months up to 48 months
  3. Written informed consent

Exclusion Criteria

  1. Nephrotic syndrome known to be secondary to a systemic disorder, e.g., Immunoglobulin A (IgA) nephropathy, systemic lupus erythematosus, Henoch Schonlein purpura, vasculitis, , hepatitis B or Alport syndrome.
  2. Persistent estimated glomerular filtration rate (GFR) <75 ml/min/1.73 m2,
  3. Therapy with prednisolone for prior episodes of nephrotic syndrome,
  4. Therapy with corticosteroids in the past 3 months, in a dose more than 1 mg/kg for >14 days for any other reason,
  5. Corticosteroid therapy for initial episode of nephrotic syndrome prior to randomization varying from pre-specified protocol on more than 14 days,
  6. Patients who show relapse during the first 3 months of pre-randomization corticosteroid therapy for nephrotic syndrome,
  7. Unclear treatment history,
  8. Gross hematuria,
  9. Patients with initial steroid resistance,
  10. Participation in any other drug study during the course of this study.
  11. Participation in more than one study without approval from the researchers involved in each study,

Sites / Locations

  • Cedars-Sinai Medical Center, Pediatric IBD & Pediatric Nephrology
  • Stanford University Medical Center, Department of Pediatrics, Division of Nephrology
  • University of Michigan Department of Pedatric Nephrology
  • Levine's Children/Carolinas HealthCare System
  • All India Institute of Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention: Prednisolone

No intervention

Arm Description

Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks

Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization

Outcomes

Primary Outcome Measures

Relapse of nephrotic syndrome during 12 months after randomization
Proportion of patients with one or more relapse(s) of nephrotic syndrome

Secondary Outcome Measures

Number of relapses during 12 months follow up
Number of nephrotic syndrome relapses per patient year during the 12-month period following randomization
Time to first relapse (days)
Number of days from randomization to occurrence of first relapse
Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization
Proportion of patients with frequent relapses during the 12 months post randomization
Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period from randomization
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization
The use of steroid-sparing medications
The proportion of patients in each study arm treated with steroid-sparing strategies or medications, e.g., levamisole, cyclophosphamide, mycophenolate mofetil and calcineurin inhibitors
Adverse events during 12-month period after randomization
Number and types of adverse events experienced, related or unrelated to corticosteroid use
Change in anthropometry and growth velocity during 12-month period after randomization
Changes in standard deviation scores (SDS) for weight, height and body mass index during 12-month period following randomization

Full Information

First Posted
March 17, 2017
Last Updated
September 6, 2020
Sponsor
All India Institute of Medical Sciences, New Delhi
Collaborators
NephCure Accelerating Cures Institute, University of Michigan, Department of Biotechnology, Government of India (funding agency)
search

1. Study Identification

Unique Protocol Identification Number
NCT03141970
Brief Title
Prednisolone Trial in Children Younger Than 4 Years
Official Title
Randomized, Multicentric, Open Label, Parallel Group Trial to Compare the Efficacy of 6-months Versus 3-months Therapy With Prednisolone for the First Episode of Idiopathic Nephrotic Syndrome in Children Younger Than 4 Years
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2015 (Actual)
Primary Completion Date
October 31, 2020 (Anticipated)
Study Completion Date
October 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
All India Institute of Medical Sciences, New Delhi
Collaborators
NephCure Accelerating Cures Institute, University of Michigan, Department of Biotechnology, Government of India (funding agency)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a multicentric, randomized, parallel group, open label controlled trial of children age 1 year up to 4 years with new onset, idiopathic nephrotic syndrome. It is designed to test the initial duration of steroid therapy of either 3 month or 6 month total duration. Participants will be randomized to either extend their pre-trial 3 months (12 weeks) of standard of care corticosteroid therapy to add an additional 12 weeks of therapy or to stop therapy. Pre-trial standard of care corticosteroids will include 60 mg/m2/day for 6 weeks followed by 40 mg/m2/day every other day for 6 weeks of prednisolone or equivalent. The trial intervention will therefore be an additional 12 vs 0 weeks of corticosteroids in these children with idiopathic nephrotic syndrome.
Detailed Description
Trial Registration Note:This trial was initially registered in the Indian Registry (list the number) on (date) prior to enrolling participants. The present listing shows this status of currently enrolling. New sites in the United States are expected to open within the coming year. At that time the answers to some questions, such as "Studies FDA regulated drug" will change because the basis for FDA regulation will reside on the presence of US sites and the use of US manufactured drug, whereas at this time the drug is not of US manufacture, and the trial is not currently conducted in the United States. This registration is being posted at this time to prepare to meet United States FDAAAA registration requirements. Nephrotic syndrome is a common renal disorder in children characterized by proteinuria, hypoalbuminemia and edema. The long-term prognosis for steroid-sensitive nephrotic syndrome is excellent for resolution of disease and maintenance of renal function. About 80% patients with steroid-sensitive nephrotic syndrome will relapse one or more times, requiring repeated treatment with corticosteroids. Of these, 50-60% show frequent relapses or steroid dependence and require therapy with long-term corticosteroids and other medications. Patients with multiple relapses are at risk for life-threatening infections, malnutrition and thrombotic episodes. They are also likely to show serious side effects of long-term steroid therapy and those related to use of other medications, including toxicity to bone marrow, gonads, central nervous system and kidneys. Repeated relapses also result in multiple hospitalizations and school absence. Strategies effective in reducing relapse rates and proportion of patients with frequent relapses or steroid dependence shall therefore be extremely valuable in improving the long-term management of nephrotic syndrome. Based on information from multiple studies that prolonged duration of initial therapy beyond 8-weeks reduced the risk of an early relapse and lowered frequency of subsequent relapses, it is agreed upon that the initial therapy with prednisolone should continue for 12 weeks (3 months), administered daily for a duration of 6 weeks, and then on alternate days for another 6 weeks. However, the optimal dose and duration of corticosteroid therapy remains to be determined. Data from various prospective studies, systematically reviewed in the Cochrane Registry, suggests the beneficial effects of prolongation of treatment beyond 3 months, with benefit seen up to 6-months. However, the advantages of extending therapy from 3- to 6-months are not unambiguous; there are also concerns of the corticosteroid toxicity with the latter regimens. Recent placebo controlled trials reported in 2013, including from this center, suggest that extending initial prednisolone treatment from 3 months to 6 months, with or without an increase in cumulative dose, does not influence the course of disease in children with nephrotic syndrome. However, in the study conducted in India, we found that prolonged therapy was useful in postponing the first relapse, and was associated with an insignificantly decreased risk of frequent relapses, in the subgroup of children younger than 4 years. Since the subgroups were not defined a priori, a prospective study is required to clarify the efficacy of this intervention in young patients. Further, the lack of clarity regarding disease pathogenesis makes the administration of corticosteroid therapies largely empirical. While clear insight into the pathogenic pathways targeted by prednisolone is lacking, there is some evidence that disease remission is associated with down regulation of T cell activation, altered B-T cell crosstalk, upregulation of T helper type 1(Th1) and/or T regulatory compartments. This present study proposes to examine the benefits of prolongation of initial therapy of idiopathic nephrotic syndrome from the current standard of 3 to 6 months among children younger than 4-yr-old an onset of disease. Prolongation of treatment at the first episode would have considerable promise, if found effective in reducing future relapses and without concomitant risks of corticosteroid toxicity. The proposal also aims to examine the proportions of T and B lymphocyte subsets in 20 patients with the initial episode of nephrotic syndrome. The evaluation shall be conducted at onset of disease, following prednisolone induced disease remission, and at one year from randomization or at first relapse of the disease to determine differences in the immune profiles at different stages of the disease. Apart from improving our knowledge of pathogenesis of nephrotic syndrome, this approach shall enhance our understanding of the immunological alterations influenced by therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nephrotic Syndrome
Keywords
Proteinuria Hypoproteinemia Edema Hypoalbuminemia Prednisone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Multicentric, Parallel group, Open label randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention: Prednisolone
Arm Type
Experimental
Arm Description
Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
Arm Title
No intervention
Arm Type
No Intervention
Arm Description
Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
Intervention Type
Drug
Intervention Name(s)
Prednisolone
Other Intervention Name(s)
Prednisone
Intervention Description
Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
Primary Outcome Measure Information:
Title
Relapse of nephrotic syndrome during 12 months after randomization
Description
Proportion of patients with one or more relapse(s) of nephrotic syndrome
Time Frame
12 month period following randomization
Secondary Outcome Measure Information:
Title
Number of relapses during 12 months follow up
Description
Number of nephrotic syndrome relapses per patient year during the 12-month period following randomization
Time Frame
12 month period following randomization
Title
Time to first relapse (days)
Description
Number of days from randomization to occurrence of first relapse
Time Frame
12 month period following randomization
Title
Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization
Description
Proportion of patients with frequent relapses during the 12 months post randomization
Time Frame
12 month period following randomization
Title
Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period from randomization
Description
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization
Time Frame
12 month period following randomization
Title
The use of steroid-sparing medications
Description
The proportion of patients in each study arm treated with steroid-sparing strategies or medications, e.g., levamisole, cyclophosphamide, mycophenolate mofetil and calcineurin inhibitors
Time Frame
12 month period following randomization
Title
Adverse events during 12-month period after randomization
Description
Number and types of adverse events experienced, related or unrelated to corticosteroid use
Time Frame
12 month period following randomization
Title
Change in anthropometry and growth velocity during 12-month period after randomization
Description
Changes in standard deviation scores (SDS) for weight, height and body mass index during 12-month period following randomization
Time Frame
12 month period following randomization
Other Pre-specified Outcome Measures:
Title
In a subgroup of 20 patients, the proportions of the following cell subsets, at baseline and at 6 and 12 months after randomization and at first relapse
Description
Proportions of B (naive, memory, regulatory) and T (cytotoxic, helper 1, helper 2, helper 17, regulatory) cell subsets, as determined by flow cytometric staining for specific surface and intracellular markers
Time Frame
12 month period following randomization
Title
Relapse of nephrotic syndrome during 24 months after randomization
Description
Proportion of patients with one or more relapse(s) of nephrotic syndrome
Time Frame
24 month period following randomization
Title
Number of relapses during 24 months follow up
Description
Number of nephrotic syndrome relapses per patient year during the 24-month period
Time Frame
24 month period following randomization
Title
Time to first relapse (days)
Description
Number of days from randomization to occurrence of first relapse
Time Frame
24 month period following randomization
Title
Occurrence of frequent relapses of nephrotic syndrome during 24 months from randomization
Description
Proportion of patients with frequent relapses during the 24 months post randomization
Time Frame
24 month period following randomization
Title
Cumulative prednisolone [or corticosteroid equivalent] received during 24 month period
Description
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 24 months from randomization
Time Frame
24 month period following randomization
Title
Relapse of nephrotic syndrome during 12 months after randomization in boys compared to girls
Description
Proportion of patients with one or more relapse(s) of nephrotic syndrome in boys compared to girls
Time Frame
12 month period following randomization
Title
Relapse of nephrotic syndrome during 12 months after randomization in patients <2-yr-old at randomization compared to older patients
Description
Proportion of patients with one or more relapse(s) of nephrotic syndrome in patients <2-yr-old at randomization compared to older patients
Time Frame
12 month period following randomization
Title
Relapse of nephrotic syndrome during 12 months after randomization in Indian patients compared to those in the USA
Description
Proportion of patients with one or more relapse(s) of nephrotic syndrome in Indian patients compared to those in the USA
Time Frame
12 month period following randomization
Title
Number of relapses during 12 months follow up in boys compared to girls
Description
Number of nephrotic syndrome relapses per patient year during the 12-month period in boys compared to girls
Time Frame
12 month period following randomization
Title
Number of relapses during 12 months follow up in patients <2-yr-old at randomization compared to older patients
Description
Number of nephrotic syndrome relapses per patient year during the 12-month period in patients <2-yr-old at randomization compared to older patients
Time Frame
12 month period following randomization
Title
Number of relapses during 12 months follow up in Indian patients compared to those in the USA
Description
Number of nephrotic syndrome relapses per patient year during the 12-month period in Indian patients compared to those in the USA
Time Frame
12 month period following randomization
Title
Time to first relapse (days) in boys compared to girls
Description
Number of days from randomization to occurrence of first relapse in boys compared to girls
Time Frame
12 month period following randomization
Title
Time to first relapse (days) in patients <2-yr-old at randomization compared to older patients
Description
Number of days from randomization to occurrence of first relapse in patients <2-yr-old at randomization compared to older patients
Time Frame
12 month period following randomization
Title
Time to first relapse (days) in Indian patients compared to those in the USA
Description
Number of days from randomization to occurrence of first relapse in Indian patients compared to those in the USA
Time Frame
12 month period following randomization
Title
Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in boys compared to girls
Description
Proportion of patients with frequent relapses during the 12 months post randomization in boys compared to girls
Time Frame
12 month period following randomization
Title
Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in patients <2-yr-old at randomization compared to older patients
Description
Proportion of patients with frequent relapses during the 12 months post randomization in patients <2-yr-old at randomization compared to older patients
Time Frame
12 month period following randomization
Title
Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in Indian patients compared to those in the USA
Description
Proportion of patients with frequent relapses during the 12 months post randomization in Indian patients compared to those in the USA
Time Frame
12 month period following randomization
Title
Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in boys compared to girls
Description
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in boys compared to girls
Time Frame
12 month period following randomization
Title
Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in patients <2-yr-old at randomization compared to older patients
Description
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in patients <2-yr-old at randomization compared to older patients
Time Frame
12 month period following randomization
Title
Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in Indian patients compared to those in the USA
Description
Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in Indian patients compared to those in the USA
Time Frame
12 month period following randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Idiopathic, steroid-sensitive, first episode of nephrotic syndrome Age 12 months up to 48 months Written informed consent Exclusion Criteria Nephrotic syndrome known to be secondary to a systemic disorder, e.g., Immunoglobulin A (IgA) nephropathy, systemic lupus erythematosus, Henoch Schonlein purpura, vasculitis, , hepatitis B or Alport syndrome. Persistent estimated glomerular filtration rate (GFR) <75 ml/min/1.73 m2, Therapy with prednisolone for prior episodes of nephrotic syndrome, Therapy with corticosteroids in the past 3 months, in a dose more than 1 mg/kg for >14 days for any other reason, Corticosteroid therapy for initial episode of nephrotic syndrome prior to randomization varying from pre-specified protocol on more than 14 days, Patients who show relapse during the first 3 months of pre-randomization corticosteroid therapy for nephrotic syndrome, Unclear treatment history, Gross hematuria, Patients with initial steroid resistance, Participation in any other drug study during the course of this study. Participation in more than one study without approval from the researchers involved in each study,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arvind Bagga, MD
Organizational Affiliation
All India Institute of Medical Sciences, New Delhi, India
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Debbie Gipson, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cedars-Sinai Medical Center, Pediatric IBD & Pediatric Nephrology
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Stanford University Medical Center, Department of Pediatrics, Division of Nephrology
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
University of Michigan Department of Pedatric Nephrology
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Levine's Children/Carolinas HealthCare System
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
All India Institute of Medical Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110029
Country
India

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Following anonymisation to protect patient identity, data from patients in USA will be pooled and analyzed with that from Indian patients. Data will be available once all subjects have completed the study and data has been analyzed. No interim data analysis will be conducted
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
http://ctri.nic.in/Clinicaltrials/login.php
Available IPD/Information Identifier
CTRI/2015/06/005939
Available IPD/Information Comments
Contains details of registration of clinical trial prior to recruiting patients in India, at website of Clinical Trials Registry of India

Learn more about this trial

Prednisolone Trial in Children Younger Than 4 Years

We'll reach out to this number within 24 hrs